A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancyGRAHAM, Janet S; FALK, Stephen; SAMUEL, Leslie M et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 945-952, issn 0344-5704, 8 p.Article

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaJONES, Robert J; HAWKINS, Robert E; EATOCK, Martin M et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 435-441, issn 0344-5704, 7 p.Article

Cancer cell senescence: a new frontier in drug developmentCAIRNEY, Claire J; BILSLAND, Alan E; JEFFRY EVANS, T. R et al.Drug discovery today. 2012, Vol 17, Num 5-6, pp 269-276, issn 1359-6446, 8 p.Article

Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic FactorsOLMOS, David; A'HERN, Roger P; SCHELLENS, Jan H et al.Journal of clinical oncology. 2012, Vol 30, Num 9, pp 996-1004, issn 0732-183X, 9 p.Article